ORPHA:83482
Mycoplasma encephalitis
Publications
56
43.8th percentile
Trials
0
Interventional, condition-specific
Researchers
265
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Mycoplasma encephalitis is a rare infectious encephalitis characterized by an acute onset of neurological signs and symptoms (e.g. altered consciousness, , headaches, meningeal signs, behavioral changes) due to bacterial infection by Mycoplasma pneumoniae. Patients typically present unspecific signs and symptoms, such as fever, nausea, vomiting, fatigue, prior to onset of neurological manifestations and frequently have a history of a respiratory tract infection (e.g. pneumonia, bronchiolitis, pharyngitis).
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019377
- UMLS:C4707240
Additional Mondo synonyms (2)
Mycoplasma pneumoniae caused infectious encephalitis · Mycoplasma pneumoniae infectious encephalitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
56 matched papers (30 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 203 for broader category encephalitis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
56
56 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
56 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
30 in the last 10 years · high confidence · 43.8th percentile (publications denominator)
Phrase hits: 56 · MeSH hits: 0
Who's working on it?
265
Distinct author names in 56 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Wang C3 papers · 2023
Department of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Papers in Europe PMC - 02Li X2 papers · 2023
Department of Pediatrics, Jinhua Hospital of Zhejiang University, Jinhua Municipal Central Hospital, Jinhua, 321000, Zhejiang Province, China.
Papers in Europe PMC - 03Liu G2 papers · 2025
Department of Infectious Diseases Beijing Children's Hospital Capital Medical University National Center for Children's Health Beijing China.
Papers in Europe PMC - 04Zhang Y2 papers · 2024
Department of Critical Care Medicine, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai, China.
Papers in Europe PMC - 05Agborndip E1 paper · 2017
Health Education and Research Organization, Buea, Cameroon.
Papers in Europe PMC - 06Ai L1 paper · 2023
Department of Neurology, Hunan Children's Hospital, Changsha, China.
Papers in Europe PMC - 07Akkus A1 paper · 2020
General pediatrics, Dr Sami Ulus Gynecology Obstetrics and Child Health and Diseases Training and Research Hospital, Ankara, Turkey.
Papers in Europe PMC - 08Aksoy A1 paper · 2020
Pediatric Neurologists, Ondokuz Mayis University, Samsun, Turkey.
Papers in Europe PMC - 09Aldosari M1 paper · 2016
Department of Pediatric Neurology & Neurosurgery, Cleveland Clinic Foundation, Cleveland, OH, USA.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 203 trials are registered for encephalitis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
203 interventional trials matched encephalitis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: encephalitis
203
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07131683·NOT YET RECRUITING·hUC-MSC-Exo Therapy for Autoimmune Encephalitis
Conditions: Autoimmune Encephalitis·Matched via name phrase
- NCT06079294·RECRUITING·Impact of Confirmed Autoimmune Encephalitis on Brain Glucose Metabolism
Conditions: Autoimmune Encephalitis·Matched via name phrase
- NCT05586581·RECRUITING·SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy
Conditions: HIV Associated Neurocognitive Disorder · HIV Dementia · HIV Encephalitis · Healthy·Matched via name phrase
- NCT07584525·RECRUITING·Dexamethasone in Tick-borne Encephalitis
Conditions: Tick-Borne Encephalitis·Matched via name phrase
- NCT06510283·RECRUITING·Efficacy and Safety of Taitacept in Treatment of Refractory or Recurrent Anti-NMDAR/anti-LGI1 Encephalitis
Conditions: Anti-N-Methyl-D-Aspartate Receptor Encephalitis·Matched via name phrase
- NCT06939166·RECRUITING·Universal Chimeric Antigen Receptor T-Cell (UCAR T-cell) Therapy Targeting CD19/B Cell Maturation Antigen (CD19/BCMA) in Patients With r/r Neurological Autoimmune Diseases
Conditions: Neuromyelitis Optica Spectrum Disorders · Myasthenia Gravis · Multiple Sclerosis · Chronic Inflammatory Demyelinating Polyradiculoneuropathy·Matched via name phrase
- NCT07707739·NOT YET RECRUITING·Plasma Exchange in Pediatric Autoimmune Encephalitis
Conditions: Autoimmune Encephalitis (AE)·Matched via name phrase
- NCT04421846·RECRUITING·Study of Pathophysiology of Status Epilepticus and Dysimmune Encephalitis
Conditions: Status Epilepticus · Dysimmune Encephalopathy·Matched via name phrase
- NCT07432113·NOT YET RECRUITING·Prediction of Infectious Agents in the Biofire® FilmArray bioMérieux Meningitis/Encephalitis Panel Based on Clinical Syndrome and Cerebrospinal Fluid Parameters: a Diagnostic Stewardship Proposal.
Conditions: Meningitis · Encephalitic Infection · Encephalitis · Meningitis, Fungal·Matched via name phrase
- NCT07093333·RECRUITING·A Study in Participants With Anti-NMDAR Encephalitis and Anti-NMDAR Autoantibody-Associated Psychiatric Disease
Conditions: Anti-N-methyl-D-aspartate Receptor (NMDAR) Encephalitis (ANRE) · Anti-N-methyl-D-aspartate Receptor (NMDAR) Antibody-associated Psychiatric Disease · Autoimmune Encephalitis·Matched via name phrase
- NCT07583641·NOT YET RECRUITING·A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults
Conditions: Autoimmune Encephalitis (AE)·Matched via name phrase
- NCT04561557·RECRUITING·Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System
Conditions: Autoimmune Diseases · Autoimmune Diseases of the Nervous System · Neuromyelitis Optica Spectrum Disorder · Myasthenia Gravis·Matched via name phrase
- NCT07377253·NOT YET RECRUITING·First-in-Human Study Testing a New Antibody Treatment for Tick-Borne Encephalitis in Healthy Volunteers.
Conditions: The Tick-borne Encephalitis Virus (TBEV)·Matched via name phrase
- NCT07686042·NOT YET RECRUITING·Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis
Conditions: Autoimmune Encephalitis (AE) · Autoimmune Cerebellitis·Matched via name phrase
- NCT07526493·RECRUITING·Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.
Conditions: Multiple Sclerosis (MS) · Neuromyelitis Optica Spectrum Disorder (NMOSD) · Autoimmune Encephalitis (AE) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Mycoplasma encephalitis" OR "Mycoplasma pneumoniae caused infectious encephalitis" OR "Mycoplasma pneumoniae infectious encephalitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Mycoplasma encephalitis" OR "Mycoplasma pneumoniae caused infectious encephalitis" OR "Mycoplasma pneumoniae infectious encephalitis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"encephalitis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:38:38.683Z
